OR WAIT null SECS
© 2023 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
Ferring Pharmaceuticals will expand its biologics capabilities at its headquarters and manufacturing site in Saint-Prex, Switzerland.
Ferring Pharmaceuticals, a biopharmaceutical company specializing in reproductive medicine, announced on Feb. 14, 2018 that it is making a CHF 30-million (US$32 million ) investment in a new biotech center to expand its capabilities in biologics
The center, which will be installed at the company’s existing headquarters and manufacturing site in Saint-Prex, Switzerland, over the course of three years, will incorporate discovery and development capabilities for monoclonal antibodies (mAbs) as well as biologics manufacturing capabilities. The active pharmaceutical ingredient for the company’s fertility treatment, Rekovelle (follitropin delta), will also be manufactured at the new center.
“Ferring is committed to investing in innovative technology platforms to create new solutions for patients in our core areas of reproductive medicine and women’s health, gastroenterology, and urology,” said Michel Pettigrew, president of the executive board and chief operating officer at Ferring, in a company press release. “This significant investment in state-of-the art manufacturing and development technologies fits our strategy to address unmet patient needs in these areas and will open up additional opportunities for Ferring to help people live better lives.”
Additionally, in early 2018, Ferring announced a worldwide license agreement with Ligand Pharmaceuticals to use Ligand’s OmniAb platform to discover new human mAbs and accelerate development solutions for unmet patient needs in reproductive medicine and women’s health, urology, and gastroenterology. Together, these investments significantly expand Ferring’s growing capabilities in biologics, according to the company.